Indian pharmaceutical company NATCO Pharma has introduced generic Pomalidomide capsules in the United States to treat certain blood and bone marrow cancers, including multiple myeloma and Kaposi sarcoma. The launch has been carried out in partnership with Breckenridge Pharmaceutical, Incorporated, which will help distribute the medicine across the US market. The new product serves as a generic version of Celgene’s widely used oncology drug Pomalyst.
The medication will be available in four dosage strengths, including 1 milligram, 2 milligrams, 3 milligrams, and 4 milligrams. Distribution will primarily take place through specialty pharmacies and oncology clinics across the country, ensuring the treatment reaches patients who require advanced cancer therapies. By launching this generic alternative, NATCO aims to improve accessibility while providing a more affordable treatment option for individuals undergoing cancer care.
Industry data indicates that Pomalidomide capsules generated approximately $3.2 billion in sales in the United States during the 12 months ending in September 2025. The high sales figures highlight the strong demand for therapies that treat complex blood cancers such as multiple myeloma. With the introduction of its generic version, NATCO expects to tap into this significant market opportunity while strengthening its presence in the specialty generics segment.
According to information provided by the US Food and Drug Administration, NATCO believes it has secured 180 days of shared marketing exclusivity for the product. This exclusivity period may allow the company to establish a strong foothold in the US oncology generics market before broader competition emerges.
Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer of NATCO Pharma, stated that the launch represents another milestone in expanding the company’s oncology and specialty drug portfolio in the United States. He emphasized that NATCO’s long-term objective is to make complex and specialized treatments more accessible to patients worldwide.
Leadership at Breckenridge Pharmaceutical also highlighted the importance of delivering reliable and affordable generic medicines. The company noted that patient cost-sharing assistance programs will be available to help eligible individuals reduce financial burdens and avoid delays in receiving treatment. Such initiatives are designed to support patients throughout their therapy and maintain continuity in care.
The introduction of generic Pomalidomide reflects NATCO Pharma’s broader strategy of developing and commercializing complex pharmaceutical products for global markets. By focusing on therapies that address serious medical conditions, the company aims to improve treatment availability and affordability in areas where patients often face limited access to advanced medications.
